EL PASO, Texas -- (BUSINESS WIRE) -- Premier Biomedical, Inc., (OTCBB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has signed an agreement with Printed Device Concepts, Inc. (PDC) of El Paso, TX to design and fabricate a patent-pending Sequential Dialysis Machine that is critical to advancing the corporation’s medications and procedures via anticipated clinical trials beginning as early as this calendar year. Premier has filed over a dozen pending provisional patent applications in the United States and the E.U. addressing a number of diseases previously regarded as incurable or “difficult”, such as breast cancer, Alzheimer’s disease, ALS, multiple sclerosis (MS), and traumatic brain injury (TBI). Design progress meetings between Premier Biomedical, Inc. (PBI) and Printed Device Concepts are being held coincident with PBI’s other R&D partners, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center (WBAMC) and the University of Texas at El Paso (UTEP).
Premier Biomedical CEO, William A. Hartman, stated, “We have taken a strategically important step with Printed Device Concepts to design and build an actual working version of this patent-pending device. It is anticipated that this first machine will be a fully functioning machine that will not only permit us to support planned near-term clinical trials of our revolutionary technology, but will also serve as a test-bed prototype for more cost-effective versions we intend to put into production to support commercialization of our technology for more effectively treating diseases.”
Printed Device Concepts President Dan W. Muse said of the recent agreement with Premier, “We are honored to take part in the development of such a profound technology. The project with Premier is critical to our growth and the diversity of our services. The collaboration will ultimately benefit both companies by reducing to practice some of the most revolutionary medical therapies ever proposed while enabling manufacturing and technology job growth in the border region, which has seen significant investment in infrastructure, and where technology stakeholders and talent are plentiful.”
Other recent announcements by Premier Biomedical include 1) Participation in the #C4CT Concussion Awareness Summit at the United Nations during Super Bowl Week. 2) Acceptance by the American Association for Cancer Research (AACR) of PBI’s duplicated studies on their newest breast cancer treatment at AACR’s annual meeting in San Diego in April, 2014, and 3) Execution of an equity funding agreement with Kodiak Capital Group enabling PBI to pay off all of its current liabilities and having sufficient capital to fund its accelerated R&D programs for the foreseeable future.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and US Department of Defense, specifically targeting the treatment of Alzheimer's disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with business offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
About Printed Device Concepts, Inc.
Printed Device Concepts, Inc. is a technology spin-off company from the University of Texas at El Paso (UTEP). As the commercial result of a decade of additive manufacturing research at the university, PDC offers product development and advanced manufacturing services for the aerospace and defense, biomedical, energy, and automotive markets.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.